A combined clinical and biomarker approach to predict diuretic response in acute heart failure

Clinical Research in Cardiology

Volumn 105, Issue 2, 2016, Pages 145-153

  ter Maaten, Jozine M ^a   Valente, Mattia A E ^a   Metra, Marco ^b   Bruno, Noemi ^c   O’Connor, Christopher M ^d   Ponikowski, Piotr ^e   Teerlink, John R ^f   Cotter, Gad ^g   Davison, Beth ^g   Cleland, John G ^h   Givertz, Michael M ⁱ   Bloomfield, Daniel M ^j   Dittrich, Howard C ^k   van Veldhuisen, Dirk J ^a   Hillege, Hans L ^a   Damman, Kevin ^a   Voors, Adriaan A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g Momentum Research Inc   (United States)

^h UNIVERSITY OF HULL   (United Kingdom)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k UNIVERSITY OF IOWA   (United States)

more..

Author keywords

Biomarkers; Diuretic response; Heart failure; Prediction

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; FUROSEMIDE; GALECTIN 3; KIDNEY INJURY MOLECULE 1; LYMPHOTOXIN BETA RECEPTOR; MYELOPEROXIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TUMOR NECROSIS FACTOR RECEPTOR 1; DIURETIC AGENT; ELECTROLYTE;

ACUTE HEART FAILURE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIURETIC ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION; ACUTE DISEASE; ATHEROSCLEROSIS; CLINICAL TRIAL; COMPLICATION; HEART FAILURE; KIDNEY DISEASE; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ACUTE DISEASE; ATHEROSCLEROSIS; BIOMARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DIURETICS; ELECTROLYTES; FUROSEMIDE; HEART FAILURE; HUMANS; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84957846974     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-015-0896-2     Document Type: Article

References (27)

1. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House AA, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, Acute Dialysis Quality (ADQI) consensus group (2010) Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 31:703–711
2. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL (2014) Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35:1284–1293
3. Voors AA, Davison BA, Teerlink JR, Felker GM, Cotter G, Filippatos G, Greenberg BH, Pang PS, Levin B, Hua TA, Severin T, Ponikowski P, Metra M, RELAX-AHF Investigators (2014) Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome-an analysis from RELAX-AHF. Eur J Heart Fail 16:1230–1240
4. Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Mansoor GA, Bloomfield DM, Ponikowski P, O’Connor CM, Metra M, Massie BM, PROTECT Steering Committee, Investigators, and Coordinators (2010) Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail 16:25–35
5. Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC, PROTECT Investigators and Committees (2010) Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363:1419–1428
6. Shmueli G (2010) To explain or to predict? Stat Sci 25:289–310
7. Ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA (2015) Diuretic response in acute heart failure-pathophysiology, evaluation, and therapy. Nat Rev Cardiol 12:184–192
8. Kunau RT Jr, Weller DR, Webb HL (1975) Clarification of the site of action of chlorothiazide in the rat nephron. J Clin Invest 56:401–407
9. Channer KS, McLean KA, Lawson-Matthew P, Richardson M (1994) Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 71:146–150
10. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW (1993) Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 71:21A–28A
11. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H (2014) Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med 25:67–72
12. Rohatgi A, Owens AW, Khera A, Ayers CR, Banks K, Das SR, Berry JD, McGuire DK, de Lemos JA (2009) Differential associations between soluble cellular adhesion molecules and atherosclerosis in the Dallas Heart Study: a distinct role for soluble endothelial cell-selective adhesion molecule. Arterioscler Thromb Vasc Biol 29:1684–1690
13. Owens AW, Matulevicius S, Rohatgi A, Ayers CR, Das SR, Khera A, McGuire DK, de Lemos JA (2010) Circulating lymphotoxin beta receptor and atherosclerosis: observations from the Dallas Heart Study. Atherosclerosis 212:601–606
14. Cleland JG, Coletta A, Witte K (2006) Practical applications of intravenous diuretic therapy in decompensated heart failure. Am J Med 119:S26–S36
15. Shrestha K, Shao Z, Singh D, Dupont M, Tang WH (2012) Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol 110:1329–1335
16. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H (2013) Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. Clin Res Cardiol 102:745–753
17. Kazory A (2010) Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am J Cardiol 106:694–700
18. Schrier RW (2008) Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 1:2–5
19. Uwai Y, Saito H, Hashimoto Y, Inui KI (2000) Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther 295:261–265
20. Kim EJ, Lee MG (2001) Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. Biopharm Drug Dispos 22:147–156
21. Sweet DH, Bush KT, Nigam SK (2001) The organic anion transporter family: from physiology to ontogeny and the clinic. Am J Physiol Renal Physiol 281:F197–F205
22. Krick W, Wolff NA, Burckhardt G (2000) Voltage-driven p-aminohippurate, chloride, and urate transport in porcine renal brush-border membrane vesicles. Pflugers Arch 441:125–132
23. Kotchen TA, Luke RG, Ott CE, Galla JH, Whitescarver S (1983) Effect of chloride on renin and blood pressure responses to sodium chloride. Ann Intern Med 98:817–822
24. Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, Jasper S, Hazen SL, Klein AL (2007) Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol 49:2364–2370
25. Ndrepepa G, Braun S, Schomig A, Kastrati A (2011) Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clin Res Cardiol 100:327–333
26. Bao YS, Na SP, Zhang P, Jia XB, Liu RC, Yu CY, Mu SH, Xie RJ (2012) Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J Clin Immunol 32:587–594
27. Frioes F, Lourenco P, Laszczynska O, Almeida PB, Guimaraes JT, Januzzi JL, Azevedo A, Bettencourt P (2015) Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol 104:491–499